Survodutide
Investigational glucagon (GCGR) + GLP-1 dual agonist · once-weekly (SC) · not FDA-approved
Survodutide is an investigational dual agonist that switches on two receptors at once — the glucagon receptor (GCGR) and the GLP-1 receptor. That makes it mechanistically different from tirzepatide (which pairs GIP with GLP-1): survodutide is built on a glucagon backbone, and its glucagon arm adds two things pure GLP-1 drugs don't have — increased calorie burn at rest and direct burning of fat inside the liver. It is NOT FDA-approved; every dose is a trial dose. It is being developed in parallel for obesity (the SYNCHRONIZE program) and for fatty-liver disease (MASH), and the liver data is its standout result: in a phase 2 trial, up to 62% of patients saw MASH improve without worsening fibrosis. On pure weight loss it reached about 16.6% in phase 3 — strong, but below tirzepatide's ~20%+ — so its real differentiator is the liver, not the scale. The FDA granted it Breakthrough Therapy and Fast Track status specifically for MASH.
The short version
Survodutide is a man-made peptide designed to act on two hormone receptors at the same time: the GLP-1 receptor (the target of Ozempic and Wegovy) and the glucagon receptor. Hitting both is the whole point — the GLP-1 side curbs appetite and improves blood sugar, while the glucagon side makes the body burn more energy and pushes the liver to burn off its own stored fat.
It is investigational. It is not approved by the FDA or any major regulator, there is no approved dose, and no consumer product exists — every number you see for it comes from a clinical trial. It is being co-developed by Boehringer Ingelheim and Zealand Pharma.
What sets it apart from the better-known dual drug, tirzepatide, is its second receptor. Tirzepatide pairs GLP-1 with GIP; survodutide pairs GLP-1 with glucagon. That glucagon arm is why it is being pursued so hard for fatty-liver disease (MASH), where it has produced its most impressive results — arguably more notable than its weight-loss numbers, which trail tirzepatide's.
Molecular identity
Specs
- Molecular weight
- 4231.63 g/mol (free base)
- Molecular formula
- C192H289N47O61
- Monoisotopic mass
- 4229.10 Da
- Amino acids
- 29-residue acylated glucagon analog
- Structure / class
- Glucagon (GCGR) + GLP-1 receptor dual agonist; Ac4c at position 2, C-terminal amide, C18 diacid at Lys24 via GSGSGG-γGlu spacerPMID 36356832 (Mol Metab 2022)
- CAS / UNII
- 2805997-46-8 · 2ALA66NS64PubChem CID 168429725; FDA UNII
- Molecular target
- Glucagon receptor (GCGR) + GLP-1 receptor (dual agonist)PMID 36356832
- Half-life
- ~6–7 days (functional; secondary estimate)Phase 1 PK summariesHalf-life curve →
- Regulatory status
- Investigational; not FDA-approved (FDA Breakthrough Therapy + Fast Track for MASH)Boehringer Ingelheim / Zealand Pharma
Plain English
Mechanism
Survodutide is a dual receptor agonist — "agonist" means a molecule that switches a receptor on, and survodutide switches on two: the GLP-1 receptor and the glucagon receptor (GCGR). It is built on the glucagon peptide backbone (not the GLP-1 backbone) and engineered to engage both targets, with roughly equal potency at each in lab assays.
The GLP-1 arm is the "appetite and insulin" side. It promotes satiety (feeling full) and slows gastric emptying so you eat less, and it triggers glucose-dependent insulin release — meaning the pancreas releases insulin (the hormone that lowers blood sugar) mainly when blood sugar is high, which keeps the risk of hypoglycemia low when used alone.
The glucagon arm is the differentiator — the "burn and liver" side. Glucagon signaling raises energy expenditure (the body burns more calories at rest) and acts directly on liver cells to oxidize (burn) stored fat and reduce the making of new fat. That direct liver effect is why survodutide is being developed for MASH (metabolic-dysfunction-associated steatohepatitis — fatty-liver inflammation and scarring) independently of weight loss. A natural worry is that glucagon normally raises blood sugar, but in trials the GLP-1 arm dominated glucose control and net blood sugar improved — no excess-sugar signal appeared.
Sources:PMID 36356832PMID 38847460
Why people reach for it
Potential benefits
Survodutide pairs GLP-1 with glucagon rather than GIP — here's what draws interest to it, with its investigational status kept front and center.
- A standout liver-fat profile — Its real differentiator: in a Phase 2 trial, up to 62% of patients saw fatty-liver disease (MASH) improve without worsening fibrosis, and up to 67% had a large drop in liver fat — driven by the glucagon arm's direct action on the liver, which is what sets it apart from the GIP-based duals.
- Substantial weight loss — In the Phase 3 SYNCHRONIZE-1 obesity trial it produced about 16.6% mean weight loss over 76 weeks — strong, even if it trails Tirzepatide, and the reason it's pursued for body weight as well as the liver.
- A second arm that adds calorie burn — Beyond the GLP-1 appetite effect, its glucagon arm is studied to raise resting energy expenditure — burning more on top of eating less, the proposed basis for its results.
- Blood-sugar improvement despite the glucagon arm — Although glucagon normally raises blood sugar, in trials the GLP-1 arm dominated and net glucose improved — in a Phase 2 diabetes study it edged out Semaglutide on HbA1c.
- FDA Breakthrough Therapy status for MASH — The FDA granted it Breakthrough Therapy and Fast Track designations specifically for fatty-liver disease — a regulatory signal of how notable its liver data is, though those designations speed review, not approval.
- A convenient once-weekly schedule — Its ~6–7-day half-life (from albumin binding) supports one injection a week, independent of meals.
Sources:PMID 41187967PMID 38847460PMID 38330987PMID 36356832
What draws interest to Survodutide, based on what its supervised trials report and how it's used — not approved outcomes or medical claims. It is investigational, not FDA-approved, and every figure here comes from clinical trials, not a promise of results.
Implied timing
Best time to dose
Implied best time
Anytime (consistent, weekly)
Survodutide is taken on one fixed day each week — the day you hold it matters, the hour does not.
- Its functional half-life is about 6–7 days, so blood levels stay broadly steady across the week — there is no daily peak to align with a clock. Picking one weekday and holding it (Monday-to-Monday, Saturday-to-Saturday) is what keeps the albumin-depot level even.
- Effects build over weeks: appetite suppression and the glucagon-arm liver effect develop with steady-state exposure (reached around week 5), and weight loss accrues over months — so the timing of any single dose does not change the outcome, week-to-week consistency does.
- It can be injected with or without food; meal timing has no effect on the subcutaneous dose, though smaller, low-fat meals around injection day ease early nausea.
- The main day-to-day variable is nausea, sharpest during the steep titration — so some people pick a low-key day for the dose so any queasiness lands when it's least disruptive.
No study establishes an ideal time of day for Survodutide — this is reasoned from its ~6–7-day half-life and how it's used in trials. The usual peptide-dosing default is the midday-to-evening window, but for a once-weekly agent the real lever is the same weekday each week, not the hour.
Sources:PMID 41187967
How to run it
Dosing & protocol
Survodutide is dosed here as a subcutaneous injection, once weekly — the route used in every published trial and the form the on-page calculator is built for. There is no approved dosing label: it is investigational. Every number below is anchored to the phase 2 and phase 3 trial titration schedules, presented as what was tested — not a prescription. The cardinal rule of the class: slow escalation controls GI tolerability.
Investigational — no approved dose exists. All dose figures are phase 2 / phase 3 trial titrations, not a regulatory label. Survodutide is not an FDA-approved drug. WADA monitored (plausible S2/S0 by class), not explicitly banned as of 2026.
Trial-anchored dose / titration
Trials escalated gradually to target — the ramp is not a formality; trials that escalated faster saw higher dropout from GI side effects.
- Starting dose:
- Trials typically began at 1.2 mg SC once weekly and stepped up every 4 weeks.
- Obesity target (phase 2):
- Up to 4.8 mg/week. Phase 2 at top dose (completers): ~18.7% mean weight loss over 46 weeks; a large share reached ≥20%.
- Obesity target (phase 3, SYNCHRONIZE-1):
- 3.6 mg and 6.0 mg/week arms. At 76 weeks: 16.6% mean weight loss vs 3.2% placebo; 85.1% reached ≥5% loss vs 38.8%.
- MASH target (phase 2, LIVERAGE):
- 2.4, 4.8, and 6.0 mg/week arms. MASH resolution without fibrosis worsening: 47% / 62% / 43% vs 14% placebo. Liver-fat drop ≥30%: 63% / 67% / 57% vs 14%.
- Steady state:
- Approximately week 5, consistent with the ~6–7-day functional half-life from albumin binding.
Subcutaneous administration
Injected into subcutaneous fat, once every 7 days; site and rotation are the actionable choices.
- Injection site:
- Abdomen (staying several centimeters clear of the navel), outer thigh, or lateral hip. Rotate sites weekly so the same spot isn't used consecutively — reduces local lipohypertrophy and irritation.
- Weekly timing:
- Pick any consistent day of the week and hold it — Monday-to-Monday, Saturday-to-Saturday. Consistent spacing maintains steady albumin-depot levels. Steady state arrives around week 5.
- Food window:
- Subcutaneous administration bypasses the GI tract for absorption, so it is independent of meals. However, dose-escalation nausea is worsened by large or high-fat meals — smaller, low-fat meals on and around injection day ease the ramp period.
Cycle / duration
Survodutide's trial programs ran 48–76 weeks — it is designed for sustained use, not short cycles.
- Trial durations:
- Phase 2 obesity: 46 weeks. Phase 2 MASH: 48 weeks. Phase 3 obesity (SYNCHRONIZE-1): 76 weeks. These are program lengths, not necessarily an optimal stopping point.
- Discontinuation:
- GLP-1 / glucagon class agents produce weight regain on cessation — this is a class property, not specific to survodutide. Duration decisions are between the user and a physician; no trial has established an optimal treatment length for community use.
- Titration on restart:
- Re-titrate from a lower dose if there has been a gap of more than 2 weeks, as the class GI-accommodation window resets.
Reconstitution at a glance
The on-page calculator does this live; the quick reference for a 10 mg vial using the calculator defaults:
- Mixing:
- 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg per mL. On a U-100 (100-unit / 1 mL) insulin syringe: 2,400 mcg (2.4 mg) = 48 IU · 4,800 mcg (4.8 mg) = 96 IU.
- Why 2 mL:
- The 5,000 mcg/mL concentration keeps dose volumes in the 0.5–1.0 mL range, appropriate for subcutaneous depot injection. Use the calculator to adjust for other vial sizes or dilutions.
Substrate the signal needs
Nutritional cofactor precision
Survodutide's GLP-1 arm sharply suppresses appetite and slows gastric emptying; its glucagon arm raises resting calorie burn and drives hepatic fat oxidation. Both arms have nutritional costs to offset and substrates to supply. The groupings below follow three questions: What does the mechanism cost (MITIGATE)? What does the action consume (SUPPLY)? What does the glucagon arm specifically require (LIVER/GLUCAGON)?
Reasoned from GLP-1/glucagon class physiology and weight-loss nutrition — not a survodutide supplement trial. Supplement doses are common community ranges applied to this mechanism, not survodutide-specific findings.
Mitigate GI side effects (nausea + constipation)
The dominant cost of the GLP-1 arm is GI — concentrated during dose escalation. These are the first-line nutritional offsets.
- Nausea → ginger + B6:
- Ginger 1–2 g (capsule or tea) taken 30 minutes before injection day and for 1–2 days after during ramp-up. Pyridoxine (vitamin B6) 25–50 mg/day is a known antiemetic adjunct; it is safe at these doses and often combined with ginger for GI nausea. Both address the slowed-emptying nausea mechanism from outside the GLP-1 pathway.
- Constipation → magnesium + fiber + hydration:
- Magnesium glycinate or citrate 300–400 mg/day (acts as an osmotic stool softener, also replaces a frequently depleted electrolyte). Soluble fiber 10–15 g/day from psyllium, oats, or vegetables. A minimum of 2–3 L water daily — eating significantly less reduces food-driven hydration and the class slows gut motility.
Replenish electrolytes + micronutrients
Eating much less, plus GI losses on escalation, depletes electrolytes and micronutrients faster than normal.
- Electrolytes (Na / K / Mg):
- Sodium, potassium, and magnesium are the three most commonly depleted. A practical approach: electrolyte supplement providing ≥500 mg sodium + ≥300 mg potassium + 200–300 mg magnesium daily, or mineral-rich food (bone broth, avocado, leafy greens). Watch for symptoms of depletion: cramps, fatigue, headache, palpitations.
- Multivitamin:
- A daily broad-spectrum multivitamin covers the micronutrient gaps created by a smaller plate — particularly zinc, B vitamins, iron (in women), and fat-soluble vitamins (A/D/E/K) whose absorption depends on fat intake, which declines sharply on the class.
Supply and preserve lean mass
Survodutide produces significant weight loss; without active counter-measures, a substantial share comes from muscle. The glucagon arm itself increases amino-acid turnover in the liver, raising the protein requirement further.
- Protein target:
- 1.6–2.0 g per kg of body weight per day (0.7–0.9 g/lb). With a suppressed appetite, hit protein first at every meal — the rest of the plate fills in as hunger allows. Leucine-rich sources (whey, eggs, red meat, Greek yogurt) most efficiently stimulate muscle protein synthesis.
- Resistance training:
- 3–4 sessions/week of compound resistance work (squats, presses, rows) is the strongest evidence-backed lever for preserving lean mass during caloric restriction on GLP-1 agents. Cardio without resistance training does not protect muscle at the same rate.
- Creatine 3–5 g/day:
- Creatine monohydrate 3–5 g/day maintains intramuscular phosphocreatine stores, supporting training capacity under caloric restriction. It has a modest lean-mass preserving effect on top of resistance training and is safe indefinitely at this dose.
Glucagon-arm liver support
The glucagon arm's standout effect is hepatic fat clearance (the MASH result). Supporting that action — and noting its glucose implications — is specific to survodutide vs. pure GLP-1 agents.
- Choline 400–550 mg/day:
- Choline is essential for the liver to package and export fat as VLDL. Without adequate choline, hepatic fat can accumulate even as the glucagon arm tries to burn it. Eggs (two large eggs ≈ 300 mg), liver, and lecithin supplements are the most concentrated sources. The AI for choline is 425–550 mg/day; most people eating a reduced-calorie diet fall short.
- Omega-3 (EPA/DHA) 2–4 g/day:
- EPA/DHA reduce hepatic lipogenesis (new fat creation) and triglycerides, working in the same direction as the glucagon arm. 2–4 g combined EPA+DHA from fish oil daily. The higher end of this range has the strongest liver-fat data in MASLD studies.
- Limit fructose + alcohol:
- Both preferentially refill liver fat — directly opposing the glucagon arm's hepatic clearance effect. Refined sugars (especially high-fructose corn syrup), fruit juices, and alcohol should be minimized, not just moderated, while survodutide's glucagon action is the treatment objective.
- Glycemic awareness:
- The glucagon arm physiologically raises blood sugar (glucagon is a counter-regulatory hormone). In trials the GLP-1 arm dominated and net glucose improved, so no significant hyperglycemia signal appeared — but users with pre-diabetes or insulin resistance should monitor fasting glucose during dose escalation, since the two arms balance differently across individuals.
Combinations + timing
Stacking notes + timing windows
Survodutide is already a GLP-1 + glucagon dual agonist — stacking it with another GLP-1 (semaglutide, liraglutide) or a GLP-1/GIP dual (tirzepatide) is redundant on the shared GLP-1 axis. The useful complementary levers are the ones survodutide does not cover: amylin satiety signaling, lean-mass preservation, and GI comfort during the steep titration ramp.
Combinations reasoned from complementary mechanisms — not survodutide-combination trials, which do not exist (survodutide evidence is single-agent only). Doses are community convention. "Reached for" describes where users go, not a proven indication.
Survodutide + Cagrilintide
The only non-overlapping satiety axis: amylin signaling. This is the Cagrilintide logic — the same converging-pathways rationale as CagriSema, applied to a GLP-1/glucagon backbone instead.
- Why it works:
- Survodutide covers GLP-1 (appetite, insulin) + glucagon (energy expenditure, liver fat). Cagrilintide adds an amylin-receptor signal — a separate post-meal satiety brake that operates independently of the GLP-1 receptor. Three distinct pathways, not the same lever twice.
- The protocol:
- Survodutide at its trial-anchored titration (see above) + cagrilintide 0.3–0.6 mg SC once weekly (the phase 2 range tested in the CagriSema program; cagrilintide has no approved dose either). Both are weekly SC — they can be injected on the same day at different sites, or offset by 3 days.
- Outcome:
- Reached for on obesity and metabolic goals where survodutide alone has not reached weight nadir. The amylin axis has additive satiety without adding glucagon or incretin redundancy. Entirely reasoned — no published survodutide + cagrilintide trial exists.
Survodutide + Creatine + Resistance Training
Not a peptide stack — the lean-mass preservation protocol. Survodutide's rapid weight loss carries a significant muscle-loss cost; this combination directly addresses it.
- Why it works:
- GLP-1/glucagon-class agents produce weight loss partly from lean mass, especially without active counter-measures. Creatine monohydrate preserves phosphocreatine stores and supports training performance under caloric restriction; resistance training is the strongest evidence-backed signal for maintaining muscle protein synthesis during weight loss. The glucagon arm's increased amino-acid turnover makes protein + creatine even more relevant here.
- The protocol:
- Survodutide at titration dose + creatine monohydrate 3–5 g/day (no loading needed) + 3–4 sessions/week compound resistance training + protein 1.6–2.0 g/kg/day. The creatine dose is the same as in the cofactors section — this is not an addition, it is the same lever foregrounded as a stack decision.
- Outcome:
- Reached for by users prioritizing body composition over scale weight — preserving or building lean mass while the GLP-1/glucagon axis drives fat loss. The combination is mechanistically sound; no head-to-head trial with survodutide specifically.
Survodutide + BPC-157
GI comfort during steep dose escalation — BPC-157 for the GI lining, not for weight loss.
- Why it works:
- Survodutide's most common reason for discontinuation in trials was GI adverse events concentrated during escalation (55.3% GI AE rate in the phase 2 diabetes trial). BPC-157 is studied for gut-lining repair and reducing GI inflammation in preclinical models — a complementary, not overlapping, target to the GLP-1 GI mechanism. Different systems: one is slowing motility and emptying; the other is supporting the mucosal barrier that receives the burden.
- The protocol:
- BPC-157 250–500 mcg SC once daily during the survodutide titration phase (the first 8–12 weeks while stepping up to target dose). Once tolerability is established at a stable dose, BPC-157 can be cycled down or discontinued — it is most useful during the ramp, not indefinitely.
- Outcome:
- Reached for by users with GI sensitivity or a history of GI issues who want to blunt the ramp-period nausea and motility disruption. Entirely reasoned — no published survodutide + BPC-157 trial. BPC-157's own evidence is preclinical.
Reconstitution math
Reconstitution calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
96
Draw to this mark on a U-100 syringe
- Volume per dose
- 0.96 mL
- Doses per vial
- 2
- Concentration
- 5 mg/mL
One vial lasts
- Daily
- 2 days
- Every other day
- 4 days
- 5×/week
- 2 days
- Large draw (96 units). Double-check the vial size and dose — a mcg/mg mix-up produces values like this.
Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.
From the studies
Side effects from research
All safety information for survodutide comes from clinical trials only — there is no post-approval or long-term real-world surveillance, because the drug is not approved. Long-term safety, major cardiovascular outcomes, and the glucagon-arm-specific cardiovascular profile are not yet established; a dedicated cardiovascular-outcomes trial is part of the program.
The predominant side effects are gastrointestinal, consistent with the GLP-1 class: nausea, vomiting, and diarrhea, concentrated during the dose-escalation phase. In the phase 2 diabetes trial, GI adverse events occurred in about 55.3% of survodutide patients versus 22.0% on placebo, and discontinuations for adverse events ran about 15.9% versus 5.1% on placebo — driven by the rapid escalation.
Two other signals worth flagging: a modest increase in heart rate (a mean rise of about 2.3–7.3 bpm across doses, a known glucagon/GLP-1-class effect), and the glucagon-arm glucose question — although glucagon normally raises blood sugar, trials showed no hyperglycemia signal and net glucose improved, which is reassuring within the trial setting but not a substitute for long-term data.
Sources:PMID 38095657PMID 41187967
As reported in literature
Research dosing ranges
These are doses tested in published clinical trials, shown separately so the trial evidence is never mistaken for a recommended or approved regimen. All were given subcutaneously (under the skin) once weekly under medical supervision in investigational studies. Note the split between obesity, MASH (liver), and type 2 diabetes programs — the liver results are the standout. The phase 3 obesity figure (16.6%) is the treatment-policy estimand; the earlier phase 2 ~18.7% is a completer figure.
| Dose | Route | Model | Outcome | Sources: |
|---|---|---|---|---|
| up to 4.8 mg | SC weekly (46 wk) | Human (Phase 2 obesity, n=387, BMI ≥27, no diabetes) | ~18.7% mean weight loss at top dose (completers); a large share reached ≥20%; not yet plateaued at wk 46 | PMID 38330987 |
| 2.4 / 4.8 / 6.0 mg | SC weekly (48 wk) | Human (Phase 2 MASH, n=293, biopsy-confirmed, fibrosis F1–F3) | MASH improved w/o fibrosis worsening: 47% / 62% / 43% vs 14% placebo; ≥30% liver-fat drop: 63% / 67% / 57% vs 14% | PMID 38847460 |
| up to 2.7 mg | SC weekly (16 wk) | Human (Phase 2 type 2 diabetes, n≈411, HbA1c 7.0–10.0%) | HbA1c −1.71% (1.8 mg arm) vs semaglutide 1 mg −1.47%; greater weight loss than semaglutide | PMID 38095657 |
| 3.6 / 6.0 mg | SC weekly (76 wk) | Human (SYNCHRONIZE-1 Phase 3 obesity) | 16.6% mean weight loss vs 3.2% placebo (p<0.0001); up to 85.1% reached ≥5% vs 38.8% | PMID 41187967 |
Quick answers
Frequently asked
What is survodutide?
It is an investigational dual agonist that switches on both the glucagon receptor and the GLP-1 receptor. Built on a glucagon backbone, it is given as a once-weekly injection in trials and is being developed for both obesity and fatty-liver disease (MASH). It is co-developed by Boehringer Ingelheim and Zealand Pharma.
Is survodutide FDA-approved?
No. As of 2026 it is not approved by the FDA or any major regulator, and there is no approved dose or consumer product — every figure for it comes from a clinical trial. The FDA has granted it Breakthrough Therapy and Fast Track designations, but those speed review; they are not approval.
How is it different from tirzepatide?
Both are dual agonists, but their second receptor differs. Tirzepatide pairs GLP-1 with GIP; survodutide pairs GLP-1 with glucagon. The glucagon arm adds increased calorie burn and direct burning of liver fat — which is why survodutide is being pursued so hard for fatty-liver disease, where tirzepatide is less differentiated.
How much weight loss does it produce?
In the phase 3 SYNCHRONIZE-1 obesity trial, about 16.6% mean weight loss versus 3.2% on placebo over 76 weeks. An earlier phase 2 trial reported ~18.7% in completers. That is strong but below tirzepatide's ~20%+ — survodutide's real edge is its liver (MASH) profile, not pure weight loss.
Why is the liver (MASH) result so important?
Its glucagon arm directly pushes the liver to burn its own fat, independent of weight loss. In a phase 2 MASH trial, up to 62% of patients saw MASH improve without worsening fibrosis, versus 14% on placebo, and up to 67% had a ≥30% drop in liver fat. That liver benefit, recognized by FDA Breakthrough Therapy status, is the program's standout result.
Is survodutide banned in sport?
It is not explicitly named on the 2026 WADA Prohibited List in the sources reviewed. As a peptide-hormone agonist it would plausibly fall under WADA Category S2 (peptide hormones and mimetics), with any non-approved substance also captured under S0 — but that is an inference from its class, not a confirmed listing, so it should not be stated as settled.
Primary sources
References
- PubChem CID 168429725PubChem CID 168429725 (Survodutide)
- PMID 36356832Zimmermann et al., Mol Metab 2022 (discovery/pharmacology)
- PMID 38330987le Roux et al., Lancet Diabetes Endocrinol 2024 (phase 2 obesity)
- PMID 38847460Sanyal et al., NEJM 2024 (phase 2 MASH)
- PMID 38095657Blüher/le Roux et al., Diabetologia 2024 (phase 2 type 2 diabetes)
- PMID 41187967SYNCHRONIZE-1 phase 3 obesity (baseline-design paper)
- WADA 2026WADA 2026 Prohibited List (survodutide not named; S2/S0 by class inference)
Research use only · Not medical advice · Updated 2026-06-01